A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study

Evangelos G Papanikolaou*, Willem Verpoest, Human Fatemi, Basil Tarlatzis, Paul Devroey, Herman Tournaye

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

This pilot study investigates the role of luteal supplementation with recombinant LH in an attempt to reverse the poor reproductive outcome previously noticed after GnRH-agonist triggering of final oocyte maturation for IVF. Similar implantation rates were achieved with the novel recombinant LH luteal supplementation scheme compared with the standard luteal P protocol (25.0% vs. 26.7%, respectively). No cases of ovarian hyperstimulation syndrome (OHSS) were noticed in either group.

Original languageEnglish
Pages (from-to)1174-1177
Number of pages4
JournalFertility and Sterility
Volume95
Issue number3
DOIs
Publication statusPublished - 1 Mar 2011
Externally publishedYes

Keywords

  • Adult
  • Chorionic Gonadotropin
  • Drug Therapy, Combination
  • Female
  • Fertilization in Vitro
  • Gonadotropin-Releasing Hormone/agonists
  • Humans
  • Luteinizing Hormone/administration & dosage
  • Ovulation/drug effects
  • Ovulation Induction/methods
  • Pilot Projects
  • Pregnancy
  • Pregnancy Rate
  • Recombinant Proteins/administration & dosage

Fingerprint

Dive into the research topics of 'A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study'. Together they form a unique fingerprint.

Cite this